文献速递传染病防控与疫情报告免疫规划慢病防控与筛查

COVID-19加强针接种与长新冠风险降低:美国成年人群横断面研究

COVID-19 booster vaccine uptake and reduced risks for long-COVID: A cross-sectional study of a U.S. adult population.
PubMed 文献 · Vaccine · 2024-04-26

基于2022年美国国家健康访谈调查中8757名有COVID-19感染史的18岁及以上成年人数据,分析加强针接种与长新冠的关联。19.5%报告长新冠,接种加强针者调整后长新冠OR为0.75(95%CI 0.61-0.93),低于未接种者。研究提示加强针接种与长新冠患病率降低相关。

要点

  • 8757名有感染史的美国成年人中,19.5%报告长新冠。
  • 接种COVID-19加强针者调整后长新冠OR为0.75(95%CI 0.61-0.93),低于未接种者。
  • 研究提示加强针接种与长新冠患病率降低相关。

核心结论

  • 研究提示COVID-19加强针接种与美国成年人群长新冠患病率降低相关。
  • 作者强调优化加强针接种对减轻COVID-19长期影响的重要性。

研究设计与样本

  • 横断面研究,分析2022年美国国家健康访谈调查中8757名18岁及以上有COVID-19感染史成年人的数据。
  • 采用加权患病率和logistic回归模型,调整社会人口学与健康因素,分析自我报告的加强针接种状态与长新冠的关系。

主要发现

  • 19.5%的参与者报告长新冠。
  • 接种COVID-19加强针者调整后长新冠OR为0.75(95%CI 0.61-0.93),低于未接种者。

临床怎么用

  • 原文结论未据此给出具体临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Long-COVID (having symptoms lasting 3 months or longer post-infection) is an emerging public health concern, yet research on whether COVID-19 booster vaccines can mitigate this condition is limited. This study examined associations between booster uptake and long-COVID prevalence among U.S. adults. Data were analyzed from 8757 adults aged 18 years or older with a history of COVID-19 infection from the 2022 National Health Interview Survey. Weighted prevalence and logistic regression models examined relationships between self-reported COVID-19 booster vaccination status and long-COVID, adjusting for sociodemographics and health factors. 19.5 % reported experiencing long-COVID. Individuals receiving the COVID-19 booster vaccine had significantly lower adjusted odds of long-COVID (OR 0.75, 95 % CI 0.61-0.93) compared to unvaccinated individuals. Overall, these findings suggest that COVID-19 booster vaccination is associated with a reduced prevalence of long-COVID among the U.S. adult population, underscoring the importance of optimizing booster uptake to mitigate the long-term impacts of COVID-19.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Xie Z, Stallings-Smith S, Patel S, et al. COVID-19 booster vaccine uptake and reduced risks for long-COVID: A cross-sectional study of a U.S. adult population. Vaccine. 2024. PMID: 38670844. doi:10.1016/j.vaccine.2024.04.070

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。